Evaluating BMS-986458 Alone and With Anti-lymphoma Agents in RelapsedRefractory Non-Hodgkin Lymphoma A Phase 12 Open-Label Dose-Finding Study
Led by Bristol-Myers Squibb · Updated on 2026-10-23
460
Participants Needed
76
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a drug designed to target B-cell lymphoma 6 BCL6, in participants with relapsed or refractory non-Hodgkin lymphoma. This study also assesses BMS-986458 alone and in combination with other anti-lymphoma treatments. The trial is a phase 12, multi-center, open-label study sponsored by Bristol-Myers Squibb.
Participants receive BMS-986458 either as a single agent or combined with anti-lymphoma drugs such as Rituximab, GlofitamabObinutuzumab, Mosunetuzumab, Epcoritamab, or Golcadomide, administered at specified doses on scheduled days. The study includes several experimental parts evaluating these different treatment regimens. The goal is to find appropriate dosing and assess the safety and biological effects of these treatments.
During the study, participants undergo regular monitoring for adverse events, including serious and dose-limiting toxicities, for up to 2 years and 1 month. Researchers also evaluate treatment responses using the Lugano criteria for lymphoma, with follow-up assessments extending up to 3 years to track responses, progression-free survival, and overall survival. Participants will have clinical evaluations and laboratory tests throughout their involvement, which may last several years depending on the outcome measures being assessed.
CONDITIONS
Brief Title
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
BMS‑986458 regimens
Standard‑of‑care
What it is
An investigational oral degrader of BCL6 studied alone or combined with anti‑lymphoma agents across multiple experimental arms
Established treatments such as CAR T‑cell therapy, bispecific antibodies, or salvage chemotherapy followed by autologous stem cell transplant
Role in trial
Experimental treatment assigned in multiple arms (Part A1, A2, B1‑B3)
Not a trial arm but represents current standard options for eligible patients outside the study
Primary use
Being evaluated for safety, tolerability, and preliminary activity in relapsed or refractory NHL
Used to induce remission or control disease in relapsed or refractory NHL
How it is given or performed
Oral degrader dosed alone or in combination with anti‑lymphoma drugs per protocol in separate parts
Administered per typical protocols such as CAR T infusion, bispecific antibody administration, or chemotherapy plus transplant
Evidence status
Early phase safety and activity under investigation; clinical efficacy not yet established
Supported by extensive clinical use, guidelines, and outcomes data
Important risks
Risks under evaluation; safety profile not yet established
Known risks including infusion reactions, cytokine release syndrome or transplant‑related toxicity depending on therapy
Important limitations
Early‑phase data only; efficacy and tolerability across diverse regimens remain uncertain
Some patients may relapse after standard treatments or be ineligible for transplant or CAR T‑cell therapy
Patient impact
Not yet known; trial will measure safety and response outcomes
Can offer remission opportunities but with risk of treatment‑related toxicity or relapse
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Participants 18 years or older with frontline or relapsed/refractory non-Hodgkin lymphoma.
Must have measurable disease with at least one FDG-avid lesion or one lesion larger than 1.5 cm on CT or MRI.
Must agree to and follow a pregnancy prevention plan.
You will not qualify if you...
Participants with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or higher.
Unable to comply with study restrictions, precautions, or prohibited treatments.
Recent prior treatments: CAR-T therapy; radiotherapy within 4 weeks; systemic anticancer treatment within 5 half-lives or 4 weeks; allogeneic stem cell transplant within 6 months (for certain cohorts); autologous stem cell transplant within 3 months.
For combination cohorts with T-cell engagers: no prior allogeneic stem cell transplant, no solid organ transplant, no history of progressive multifocal leukoencephalopathy, no known or suspected hemophagocytic lymphohistiocytosis or chronic active Epstein-Barr infection.
No significant acute or chronic illness, uncontrolled infection, or lab abnormalities that increase risk.
No known or suspected central nervous system involvement.
Other protocol-defined criteria apply.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 3 years
Participants receive BMS-986458 alone or combined with other anti-lymphoma drugs at specified doses on scheduled days.
Regular visits for treatment and monitoring
Follow-up
Duration - Up to 3 years
Participants are monitored for safety, treatment response, and survival outcomes for up to 3 years after starting treatment.
Periodic assessments and evaluations
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
5
Similar Trials
Evaluating BMS-986458 Alone and With Anti-lymphoma Agents in RelapsedRefractory Non-Hodgkin Lymphoma A Phase 12 Open-Label Dose-Finding Study
Study of Talikabtagene Autoleucel NexCAR19 CAR-T Cell Therapy
in Adults With Relapsed or Refractory B-Cell Leukemia and Lymphoma
Phase 2-3 Open-Label Multicenter Trial